Therapeutic properties and safety of recombinant factor VIII and factor IX

Advances in hemophilia management in the 20th century enabled effective and early treatment of joint and other bleeds typical of this disease, also in a home setting. Prophylaxis became available as the optimal approach to prevent hemophilic arthropathy and improve patients' quality of life. To...

Full description

Saved in:
Bibliographic Details
Published inPolskie archiwum medycyny wewne̦trznej Vol. 119; no. 6; pp. 403 - 409
Main Authors Zdziarska, Joanna, Chojnowski, Krzysztof, Klukowska, Anna, Łetowska, Magdalena, Mital, Andrzej, Podolak-Dawidziak, Maria, Windyga, Jerzy, Zawilska, Krystyna
Format Journal Article
LanguageEnglish
Published Poland 01.06.2009
Subjects
Drug Contamination - prevention & control
Factor IX - adverse effects
Factor IX - therapeutic use
Factor VIII - adverse effects
Factor VIII - therapeutic use
Hemophilia A - drug therapy
Hemophilia B - drug therapy
Humans
Prion Diseases - etiology
Virus Diseases - etiology
Online AccessGet full text

Cover

More Information
Summary:Advances in hemophilia management in the 20th century enabled effective and early treatment of joint and other bleeds typical of this disease, also in a home setting. Prophylaxis became available as the optimal approach to prevent hemophilic arthropathy and improve patients' quality of life. To increase treatment safety, lyophilized plasma-derived factor VIII and IX concentrates were subjected to numerous procedures designed to decrease the risk of transmission of known and unknown pathogens. During the following years, recombinant factor VIII and factor IX preparations were developed to completely eliminate the risk. Recombinant factor concentrates were extensively studied in terms of their therapeutic properties, safety, and immunogenicity. This article reviews the current knowledge on efficacy and safety of recombinant factors VIII and IX.
ISSN:1897-9483
DOI:10.20452/pamw.721